Press Release For Immediate Release

Glenmark Generics receives USFDA approval for Norgestimate and Ethinyl Estradiol tablets

- This is Glenmark's fourth oral contraceptive product approval and the fifth hormone product approval for the US market

June 20, 2011: Glenmark Generics Inc., USA, a subsidiary of Glenmark Generics Ltd, today announced they have been granted final approval for their abbreviated new drug application (ANDA) by the United States Food and Drug Administration (U.S. FDA) for Norgestimate and Ethinyl Estradiol tablets, USP 0.18 mg/0.035 mg, 0.215 mg/0.035 mg and 0.25/0.035 mg.

Glenmark's approved product is their generic version of Ortho Tri-Cyclen® tablets by Ortho McNeil Janssen Pharmaceuticals Inc. indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Norgestimate and Ethinyl Estradiol Tablets USP are indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche.

According to IMS Health for the 12 month period ending March 2011, this triphasic 28-day regimen achieved total market sales of USD 226 million.

Glenmark remains the only Indian company to be granted ANDA approval for an oral contraceptive product and today's approval marks their fifth female hormonal product authorized for distribution by the U.S. FDA.

Glenmark has a number of ANDA's currently pending approval with the U.S. FDA in this therapeutic segment as well as a sizeable concentration of their pipeline in various stages of development.

The Company's current portfolio consists of 69 generic products authorized for distribution in the U.S. market and 40 ANDA's filed with the U.S. FDA pending approval. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio

About Glenmark Generics Limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza
Glenmark, Mumbai, India Tel: [+91 22] 40189919
Email : connect@glenmark-generics.com